Get the Stockscreener App
48.77
0.91%
-0.45
Pre-market:
47.30
-1.47
-3.01%
Celcuity Inc stock is traded at $48.77, with a volume of 1.12M.
It is down -0.91% in the last 24 hours and up +258.87% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$49.22
Open:
$48.94
24h Volume:
1.12M
Relative Volume:
1.13
Market Cap:
$1.90B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-18.20
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
-6.87%
1M Performance:
+258.87%
6M Performance:
+271.44%
1Y Performance:
+186.21%
1-Day Range:
$47.34
$49.50
1-Week Range:
$47.34
$53.85
52-Week Range:
$7.575
$53.85
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
48.77 | 2.19B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Drawdown in Celcuity Inc. May Be Nearing EndJuly 2025 Movers & Weekly Top Performers Watchlists - thegnnews.com
Candlestick Signal Suggests Reversal in Celcuity Inc.2025 Risk Factors & Safe Entry Trade Reports - beatles.ru
Celcuity announces $225M combined offerings; shares down - MSN
Celcuity price target raised to $66 from $50 at H.C. Wainwright - MSN
Celcuity stock price target raised to $66 from $50 at H.C. Wainwright - Investing.com Nigeria
Celcuity Q2 2025 Earnings Release: Mixed Signals Amid Persistent Losses - AInvest
Celcuity Posts Another Loss in Q2 2025: Earnings Miss Expectations and Weigh on Market Sentiment - AInvest
Celcuity's Gedatolisib: A Blockbuster Opportunity in Breast Cancer Therapy - AInvest
Why Celcuity (CELC) is Poised for a High-Probability Breakout in 2025 - AInvest
AI Trend Models Suggest Bounce for Celcuity Inc.2025 Support & Resistance & Low Risk High Win Rate Stock Picks - beatles.ru
Celcuity Inc. (NASDAQ:CELC) Q2 2025 Earnings Call Transcript - MSN
Celcuity: Needham Maintains Buy, PT Down to $70 from $74 - AInvest
Celcuity targets $5B addressable market as gedatolisib posts unprecedented PFS gains and patent extends to 2042 - MSN
Celcuity Stock Hits All-Time High on Gedatolisib Trial Success - AInvest
Stifel raises Celcuity stock price target to $68 on gedatolisib potential - Investing.com India
Celcuity Stock Hits All-Time High On Gedatolisib Progress - RTTNews
Celcuity's Q2 2025 Earnings Call: Unpacking Contradictions in Data Timelines, Patient Population Insights, and Regulatory Readiness - AInvest
Celcuity Q2 Results Highlight Cash Surge - AOL.com
Needham lowers Celcuity stock price target to $70 on dilution concerns - Investing.com
Is Celcuity Inc. meeting your algorithmic filter criteriaAnalyst Upgrade & Weekly Hot Stock Watchlists - Newser
Celcuity’s Strong Prospects: Buy Rating Affirmed Amidst Positive Drug Developments and Robust Financial Position - TipRanks
Celcuity’s Geda Triplet Therapy Shows Promising Phase III Results, Justifying Buy Rating - TipRanks
Jefferies raises Celcuity stock price target to $79 on positive trial data - Investing.com Australia
Predicting Celcuity Inc. trend using moving averagesJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
Celcuity Inc Q2 2025 Earnings Call Highlights: Navigating Losses and Strategic Advances - AInvest
Celcuity Reports Q2 Earnings with $455M Cash Reserve and Plans FDA NDA Filing for Gedatolisib in 2025 - AInvest
Celcuity Inc. Reports Promising Q2 2025 Results - TipRanks
Smart tools for monitoring Celcuity Inc.’s price action2025 Growth vs Value & AI Based Buy/Sell Signal Reports - Newser
Celcuity (CELC) Q2 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Celcuity Q2 2025 earnings miss forecasts, stock reacts - Investing.com Canada
Celcuity Reports 81% Increase in Operating Expenses, Q2 2025 Earnings Miss Analyst Estimates - AInvest
Transcript : Celcuity Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Celcuity Expenses Jump 81 Percent - The Globe and Mail
Celcuity Inc. SEC 10-Q Report - TradingView
Celcuity Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Celcuity Q2 Adjusted Loss Widens: A Clinical-Stage Biotechnology Company's Financial Performance - AInvest
Celcuity shares fall as second quarter loss exceeds estimates By Investing.com - Investing.com South Africa
Celcuity Q2 Adjusted Loss Widens - MarketScreener
Celcuity's Q1 2025 Earnings Miss: Weighing the Cost of Innovation in Biotech's High-Stakes Game - AInvest
Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - TradingView
Breakthrough Cancer Drug Results: Celcuity's Treatment Delivers Unprecedented Breast Cancer Survival Benefit - Stock Titan
RSI Suggests Rebound May Be Near in Celcuity Inc.July 2025 Recap & Daily Chart Pattern Signals - thegnnews.com
Celcuity : Corporate Presentation (Celcuity Investor Presentation V.6.16 Final) - MarketScreener
Diamedica Therapeutics shares rise 14.94% intraday after Celcuity's positive Phase 3 trial results. - AInvest
Is a relief rally coming for Celcuity Inc. holdersJuly 2025 Update & Daily Entry Point Alerts - Newser
Celcuity (CELC) Projected to Post Earnings on Thursday - Defense World
Celcuity CELC 2025Q2 Earnings Preview Upside Potential on Positive Clinical Trial Results - AInvest
Celcuity (CELC) Is Up 15.0% After Positive Phase 3 Results and $260 Million Capital Raise – Has The Bull Case Changed? - simplywall.st
Celcuity stock hits all-time high at 46.52 USD By Investing.com - Investing.com Nigeria
Celcuity stock hits all-time high at 46.52 USD - Investing.com India
Celcuity Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celcuity Inc Stock (CELC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dalvey David | Director |
Jul 28 '25 |
Sale |
45.12 |
9,325 |
420,767 |
0 |
2.44%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):